Janus Global Life Sciences Fund (JAGLX)

Sector Experts Seeking Growth and Innovation in Health Care



Inception Date12/31/1998
NAV (As of 11/24/15 )$56.79
Total Net Assets (As of 10/31/15)$4.71B
Annual Expense Ratio
(As of fiscal year end 9/30/14)
GROSS 0.93%
NET 0.93%

Performance (As of 9/30/15)
1 Year14.12%
3 Year29.36%
5 Year24.97%
10 Year13.08%
Morningstar (As of 10/31/15)
Overall Rating™
(Based on risk-adjusted returns)

View All Ratings

122 Funds Rated
Style Box

Returns quoted are past performance and do not guarantee future results; current performance may be lower or higher. Investment returns and principal value will vary; there may be a gain or loss when shares are sold. For the most recent month-end performance click here.

Returns greater than one year are annualized.

Straight Talk

Quarterly Commentary - Q3 2015


Quarterly returns for the health care sector were negative, underperforming the broader market.

The Fund underperformed its primary and secondary benchmarks, with our pharmaceuticals and biotechnology holdings detracting the most.

Managed health care and health care technology contributed the most to relative results.

We believe that politicians’ comments on drug prices do not present a material threat to the sector’s prospects.


Andy Acker, CFA

Andy Acker, CFA

Fund Manager since 2007
Industry since 1996